Copanlisib Plus Venetoclax in R/R DLBCL
Copanlisib Plus Venetoclax in R/R DLBCL
Active, not recruiting · NCT04572763 · Registry updated 2026-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Copanlisib Plus Venetoclax in R/R DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-07 | NCT04572763 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Bayer | 178 |
| Dana-Farber Cancer Institute | 324 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Cancer Center | Duarte | United States | 15 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Siteman Cancer Center at Washington University | St Louis | United States | 10 |